Skip to content

The efficacy of Rosa damascene extract in treatment of sexual dysfunction induced by Selective Serotonin Reuptale Inhibitors in men with Major Depressive Disorder

The efficacy of use and without use of Rosa damascene extract in treatment of sexual dysfunction induced by Selective Serotonin Reuptale Inhibitors in men with Major Depressive Disorder

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013100814333N10
Enrollment
60
Registered
2013-10-22
Start date
2013-10-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sexual dysfunction. Sexual dysfunction, not caused by organic disorder or disease

Interventions

Intervention 1: The intervention group received 3 cc Rosa damascenes drop daily for 8 weeks which was equivalent to 17 mg citronellol. Intervention 2: The control group received 3cc distilled water (p
Treatment - Drugs
Placebo
The intervention group received 3 cc Rosa damascenes drop daily for 8 weeks which was equivalent to 17 mg citronellol

Sponsors

Kermanshah University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with major depressive disorders according to DSM IV; and those who had been treated with a fixed dose of serotonin reuptake inhibitors for at least eight weeks; those who haven’t sexual disorder before begin the treatment and they affected sexual disorder with use of this medicines such as decrease of libido, erection disorder ,delay of orgasm or dis ability to become orgasm Exclusion criteria: presence of sexual dysfunction before taking serotonin reuptake inhibitors; presence of any systemic or psychiatric disorders , Thyroid disease and hyperprolactinemia or taking any medication which affects sexual activity; any history of drug or alcohol use during 6 recent months; those who have recently had significant changes in sexual activity due to their wife pregnancy, remarriage and divorce

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Days libido. Timepoint: At the beginning, 4th and 8th the week of study. Method of measurement: Asking the patient.;Libido. Timepoint: At the beginning, 4th and 8th the week of study. Method of measurement: Asking the patient.;Erection times. Timepoint: At the beginning, 4th and 8th the week of study. Method of measurement: Asking the patient.;Erection stiff. Timepoint: At the beginning, 4th and 8th the week of study. Method of measurement: Asking the patient.;Erection hardness. Timepoint: At the beginning, 4th and 8th the week of study. Method of measurement: Asking the patient.;Hardness of flow out of semen. Timepoint: At the beginning, 4th and 8th the week of study. Method of measurement: Asking the patient.;The problem of semen Amount. Timepoint: At the beginning, 4th and 8th the week of study. Method of measurement: Asking the patient.;The problem of lack of semen. Timepoint: At the beginning, 4th and 8th the week of study. Method of measurement: Asking the patient.;Sexual Satisfaction. Timepoint: At the beginning, 4th and 8th the week of study. Method of measurement: Asking the patient.;The problem of ability to become erect and keeping it. Timepoint: At the beginning, 4th and 8th the week of study. Method of measurement: Asking the patient.;Serotonin reuptake inhibitors. Timepoint: At the beginning, 4th and 8th the study week of. Method of measurement: Asking the patient.

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026